###begin article-title 0
###xml 26 30 26 30 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">MEFV</italic>
Missense Mutations in the MEFV Gene Are Associated with Fibromyalgia Syndrome and Correlate with Elevated IL-1beta Plasma Levels
###end article-title 0
###begin p 1
Conceived and designed the experiments: JS SSS. Performed the experiments: JF ZZ WL XS WS CY FC. Analyzed the data: JF ZZ JL TGK SSS. Contributed reagents/materials/analysis tools: CM RPSA. Wrote the paper: JS.
###end p 1
###begin title 2
Background
###end title 2
###begin p 3
###xml 221 229 <span type="species:ncbi:9606">Patients</span>
Fibromyalgia syndrome (FMS), a common, chronic, widespread musculoskeletal pain disorder found in 2% of the general population and with a preponderance of 85% in females, has both genetic and environmental contributions. Patients and their parents have high plasma levels of the chemokines MCP-1 and eotaxin, providing evidence for both a genetic and an immunological/inflammatory origin for the syndrome (Zhang et al., 2008, Exp. Biol. Med. 233: 1171-1180).
###end p 3
###begin title 4
Methods and Findings
###end title 4
###begin p 5
###xml 196 200 196 200 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">MEFV</italic>
###xml 355 359 355 359 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">MEFV</italic>
###xml 557 558 557 558 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">p</italic>
###xml 663 667 663 667 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">MEFV</italic>
###xml 1052 1056 1046 1050 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">MEFV</italic>
###xml 93 100 <span type="species:ncbi:9606">patient</span>
###xml 762 770 <span type="species:ncbi:9606">patients</span>
###xml 860 868 <span type="species:ncbi:9606">patients</span>
In a search for a candidate gene affecting inflammatory pathways, among five screened in our patient samples (100 probands with FMS and their parents), we found 10 rare and one common alleles for MEFV, a gene in which various compound heterozygous mutations lead to Familial Mediterranean Fever (FMF). A total of 2.63 megabases of genomic sequence of the MEFV gene were scanned by direct sequencing. The collection of rare missense mutations (all heterozygotes and tested in the aggregate) had a significant elevated frequency of transmission to affecteds (p = 0.0085, one-sided, exact binomial test). Our data provide evidence that rare missense variants of the MEFV gene are, collectively, associated with risk of FMS and are present in a subset of 15% of FMS patients. This subset had, on average, high levels of plasma IL-1beta (p = 0.019) compared to FMS patients without rare variants, unaffected family members with or without rare variants, and unrelated controls of unknown genotype. IL-1beta is a cytokine associated with the function of the MEFV gene and thought to be responsible for its symptoms of fever and muscle aches.
###end p 5
###begin title 6
Conclusions
###end title 6
###begin p 7
###xml 97 101 94 98 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">MEFV</italic>
###xml 66 74 <span type="species:ncbi:9606">patients</span>
###xml 125 133 <span type="species:ncbi:9606">patients</span>
Since misregulation of IL-1beta expression has been predicted for patients with mutations in the MEFV gene, we conclude that patients heterozygous for rare missense variants of this gene may be predisposed to FMS, possibly triggered by environmental factors.
###end p 7
###begin title 8
Introduction
###end title 8
###begin p 9
###xml 229 232 229 232 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0008480-Wolfe1">[1]</xref>
###xml 340 343 340 343 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0008480-Wolfe2">[2]</xref>
###xml 553 556 553 556 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0008480-Wolfe3">[3]</xref>
Fibromyalgia syndrome (FMS) is characterized by chronic, widespread pain in the muscles and joints. FMS is also accompanied by a variety of other common symptoms, including sleep disturbance, fatigue, headache and mood disorders [1]. The prevalence of FMS in the general population is estimated at 2%, where 85% of the affected are females [2]. The current American College of Rheumatology (ACR) criteria for diagnosis/entry into a clinical trial relies on the scoring of 11/18 positive tender points plus widespread pain lasting for more than 3 months [3]. The etiology of FMS is elusive, with proposals ranging from over-sensitivity to pain to chronic infections. Both familial and genetic studies suggest a role for genetic factors in the development of FMS.
###end p 9
###begin p 10
###xml 82 85 82 85 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0008480-Buskila1">[4]</xref>
###xml 87 90 87 90 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0008480-Arnold1">[5]</xref>
###xml 92 95 92 95 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0008480-Kato1">[6]</xref>
###xml 282 285 282 285 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0008480-Buskila2">[7]</xref>
###xml 544 547 544 547 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0008480-Buskila2">[7]</xref>
###xml 601 604 601 604 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0008480-Arnold1">[5]</xref>
###xml 428 436 <span type="species:ncbi:9606">children</span>
Family studies showed a strong familial aggregation of FMS and related conditions [4], [5], [6]. A possible role of genetic and familial factors in this syndrome was studied in 58 offspring originating from 20 complete nuclear families ascertained through affected mothers with FMS [7]. Indeed, a high prevalence of FMS was observed among offspring of FMS mothers. Since psychological and familial factors were not different in children with and without FMS, the high familial occurrence of this syndrome may be attributable to genetic factors [7]. In a more comprehensive family study, Arnold et al. [5] assessed familial aggregation of FMS with measures of tenderness and pain, and familial co-aggregation of FMS with major mood disorder. The odds ratio measuring the odds of FMS in a relative of a proband with FMS versus the odds of FMS in a relative of a proband with rheumatoid arthritis (RA) was 8.5. The number of tender points was significantly higher and the total myalgic score was significantly lower in the relatives of FMS probands compared with relatives of RA probands. The results of this study indicate that FMS and reduced pressure pain thresholds aggregate in families, and that FMS co-aggregates with major mood disorder in families. These findings have clinical and theoretical implications, including the possibility that genetic factors are involved in the etiology of FMS and pain sensitivity.
###end p 10
###begin p 11
###xml 383 386 383 386 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0008480-Crofford1">[8]</xref>
###xml 388 391 388 391 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0008480-Arnold2">[9]</xref>
###xml 393 397 393 397 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0008480-Schwarz1">[10]</xref>
###xml 399 403 399 403 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0008480-Cohen1">[11]</xref>
###xml 405 409 405 409 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0008480-Offenbaecher1">[12]</xref>
###xml 531 535 531 535 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0008480-Bondy1">[13]</xref>
###xml 537 541 537 541 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0008480-Gursoy1">[14]</xref>
###xml 1142 1146 1142 1146 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0008480-Bondy1">[13]</xref>
###xml 497 505 <span type="species:ncbi:9606">patients</span>
###xml 615 623 <span type="species:ncbi:9606">patients</span>
###xml 926 934 <span type="species:ncbi:9606">patients</span>
Studies in search of the genetic predisposition to FMS have been conducted based on the strong evidence of a familial aggregation in FMS. The genes involved in serotoninergic neurotransmission are of special interest in FMS, as this neurotransmitter not only partially mediates central pain perception, but also functions to regulate anxiety related traits often associated with FMS [8], [9], [10], [11], [12]. The silent T102C polymorphism of the 5-HT2A-receptor gene was investigated in 168 FMS patients and 115 healthy controls [13], [14]. A significantly different genotype distribution was shown, in which FMS patients had fewer T/T and more frequent T/C and C/C genotypes as compared to the control population (Fisher's exact test, two-sided, p = 0.008). Genotypes were unrelated to age of onset, duration of disease or psychopathological symptoms. Self-reported information on pain severity was significantly higher in patients of the T/T genotype, which suggested that the T102-allele might be involved in the complex circuits of nociception. The T102C polymorphism might be in linkage disequilibrium with the true functional variant [13].
###end p 11
###begin p 12
###xml 246 250 246 250 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0008480-Gursoy2">[15]</xref>
###xml 742 746 742 746 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0008480-Gursoy2">[15]</xref>
###xml 213 221 <span type="species:ncbi:9606">patients</span>
###xml 317 325 <span type="species:ncbi:9606">patients</span>
###xml 373 381 <span type="species:ncbi:9606">patients</span>
A second gene investigated, catechol-O-methyltransferase (COMT), encodes an enzyme that inactivates catecholamines and catecholamine-containing drugs. The significance of COMT polymorphisms was assessed in 61 FMS patients and 61 healthy controls [15]. The LL and LH genotypes together were more highly represented in patients than controls (p = 0.024), and HH genotypes in patients were significantly lower than in the control group (p = 0.04). It was concluded that COMT polymorphisms would be of potential pharmacological importance regarding individual differences in the metabolism of catechol drugs and may also be involved in the pathogenesis and treatment of FMS through adrenergic mechanisms, as well as genetic predisposition to FMS [15].
###end p 12
###begin p 13
###xml 133 137 133 137 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0008480-Buskila3">[16]</xref>
###xml 438 442 438 442 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0008480-Buskila4">[17]</xref>
Though several lines of evidence suggest a role for polymorphisms of genes in the serotoninergic, catecholaminergic and dopaminergic [16] systems in the etiopathogenesis of FMS, these polymorphisms are not specific for FMS and are similarly associated with additional co-morbid conditions. Currently, no evidence has emerged to point to a monogenic mode of transmission, while a multi-factorial mode of transmission is generally presumed [17].
###end p 13
###begin p 14
###xml 83 87 83 87 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0008480-Zhang1">[18]</xref>
###xml 124 128 124 128 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0008480-Buskila5">[19]</xref>
###xml 130 134 130 134 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0008480-Baio1">[20]</xref>
###xml 136 140 136 140 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0008480-Ablin1">[21]</xref>
###xml 297 301 297 301 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0008480-Sprott1">[22]</xref>
###xml 498 502 498 502 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0008480-Zhang1">[18]</xref>
###xml 691 695 691 695 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0008480-Pace1">[23]</xref>
###xml 697 701 697 701 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0008480-Sperber1">[24]</xref>
###xml 322 330 <span type="species:ncbi:9606">patients</span>
###xml 682 690 <span type="species:ncbi:9606">patients</span>
Recently, we have investigated the possibility that FMS has an immunological basis [18], an idea that remains controversial [19], [20], [21]. In support of this idea, biopsies of FMS skeletal muscles showed defects that may have been caused (among other possibilities) by an inflammatory disorder [22]. We found that both patients and their parents had high plasma levels of the chemokines MCP-1 (p<0.001) and eotaxin (p<0.01), supporting both the genetic and immunological basis for this syndrome [18]. Possible immunological triggers for FMS include intestinal inflammation such as found in irritable bowel syndrome (IBS), a condition found in a large percentage (ca. 50%) of FMS patients [23], [24].
###end p 14
###begin p 15
###xml 170 174 170 174 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">MEFV</italic>
###xml 413 417 413 417 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0008480-Samuels1">[25]</xref>
###xml 419 423 419 423 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0008480-Onen1">[26]</xref>
In a search for possible candidate genes that are associated with conditions such as inflammation of the bowel, as well as other organs, we became interested in the gene MEFV, in which a number of mutations cause Familial Mediterranean Fever (FMF). FMF is an autosomal recessive disorder characterized by recurrent attacks of fever and inflammation in the peritoneum, synovium, or pleura, and accompanied by pain [25], [26]. Clinical features show that FMS and FMF have some overlapping symptoms, such as chronic lower body pain, points of tenderness, and widespread pain.
###end p 15
###begin p 16
###xml 4 8 4 8 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">MEFV</italic>
###xml 513 517 513 517 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0008480-Franchi1">[27]</xref>
###xml 519 523 519 523 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0008480-Mathews1">[28]</xref>
###xml 525 529 525 529 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0008480-Chen1">[29]</xref>
###xml 531 535 531 535 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0008480-Ye1">[30]</xref>
###xml 633 637 633 637 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0008480-Stehlik1">[31]</xref>
###xml 639 643 639 643 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0008480-Shinkai1">[32]</xref>
###xml 803 807 803 807 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0008480-Franchi2">[33]</xref>
###xml 1040 1045 1031 1036 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">NLRP3</italic>
###xml 1049 1054 1040 1045 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">CIAS1</italic>
###xml 1112 1116 1103 1107 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0008480-Saito1">[34]</xref>
###xml 1118 1122 1109 1113 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0008480-Dinarello1">[35]</xref>
###xml 1124 1128 1115 1119 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0008480-Aksentijevich1">[36]</xref>
###xml 1130 1134 1121 1125 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0008480-Sutterwala1">[37]</xref>
###xml 1136 1140 1127 1131 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0008480-Neven1">[38]</xref>
###xml 1283 1287 1274 1278 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0008480-Berkun1">[39]</xref>
###xml 1418 1422 1409 1413 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0008480-Strober1">[40]</xref>
###xml 1577 1581 1568 1572 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0008480-Watanabe1">[41]</xref>
###xml 1733 1737 1724 1728 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0008480-Roberts1">[42]</xref>
The MEFV gene, located on chromosome 6p13.3, has 10 exons and encodes a 781 amino acid protein, termed pyrin. Pyrin contains the PYD domain, which belongs to a member of the six-helix bundle, death-domain superfamily that includes death domains, death effector domains, and caspase activation and recruitment domains (CARDs). The NLR (nucleotide binding domain and leucine rich, or NOD-like receptor, where NOD is an abbreviation for nucleotide oligomerization domain) family of genes also contain the PYD domain [27], [28], [29], [30]. While the pyrin protein is thought to function in apoptotic and inflammatory signaling pathways [31], [32], its exact function has been debated. In a better-studied system, cryopyrin or NLRP3, which also has the PYD domain, is activated to assemble the inflammasome [33], a multi-protein structure that ultimately results in activation of pro-caspase-1 that, in turn, processes pro-IL-1beta to IL-1beta. Upon release from monocytes, IL-1beta causes fever. Notably, rare mutations in the cryopyrin gene (NLRP3 or CIAS1) are dominant, leading to a variety of serious syndromes [34], [35], [36], [37], [38]. The current hypothesis for the role of pyrin in FMF is that wild type pyrin inhibits, while mutated pyrin fails to inhibit, the inflammasome [39]. This situation would be similar to the role of NOD2 in Crohn's disease, in which wild type NOD2, also a member of the NLR family [40], inhibits TLR2 (toll-like receptor-2) activation by peptidoglycan, while mutated NOD2 fails to inhibit TLR2, leading to chronic inflammation in the bowel [41]. More recently, the pyrin-domain-containing protein, HIN-200, has been shown to regulate caspase activation in response to foreign double-stranded DNA [42], further suggesting that members of the NLR gene family, especially the PYD-domain-containing members, regulate inflammation.
###end p 16
###begin p 17
###xml 49 53 49 53 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">MEFV</italic>
###xml 148 152 148 152 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">MEFV</italic>
###xml 478 482 478 482 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">MEFV</italic>
###xml 797 801 797 801 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0008480-Kryukov1">[43]</xref>
###xml 867 871 867 871 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">MEFV</italic>
To explore the possibility that mutations in the MEFV gene may predispose to FMS, we sequenced the regions of likely functional significance in the MEFV gene, exons and splice junctions, in 100 FMS probands and their parents (trios), plus a small number of affected siblings. We hypothesized that rare missense variants would, collectively, be found at elevated frequency in affected individuals. This hypothesis is based on the observation that different rare mutations in the MEFV gene (<5% population frequency) can lead to FMF when they are compound heterozygous, reports that rare mutations in the related cryopyrin gene act as dominant risk alleles for a variety of syndromes, and published theoretical arguments that low allele frequency can serve as a predictor of functional significance [43]. It is possible that rare mutations on a single haplotype in the MEFV gene cause milder symptoms than those in the compound heterozygous state associated with FMF or, more likely, that additional factors present in the environment may trigger FMS.
###end p 17
###begin p 18
###xml 536 540 536 540 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">MEFV</italic>
###xml 265 270 <span type="species:ncbi:9606">child</span>
###xml 628 636 <span type="species:ncbi:9606">patients</span>
We found 10 rare missense mutations, occurring in combinations forming 10 distinct haplotypes in 18 families in which we could follow 22 independent transmission events in which a heterozygous parent might have transmitted any of the rare haplotypes to an affected child. We tested our hypothesis by counting the transmissions from heterozygous parents to affected offspring, and found a significant transmission bias (p = 0.0085, exact binomial test, one-sided), indicating a positive association between FMS and rare mutations in the MEFV gene. Rare mutations were present in 15 of 100 probands In addition, the subset of FMS patients with rare alleles had elevated plasma levels of IL-1beta (p = 0.019). These findings further support the genetic and immunological basis of this syndrome.
###end p 18
###begin title 19
Results
###end title 19
###begin title 20
###xml 0 4 0 4 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">MEFV</italic>
MEFV Variants in FMS Trios
###end title 20
###begin p 21
###xml 162 166 162 166 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0008480-Zhang1">[18]</xref>
###xml 330 334 330 334 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">MEFV</italic>
###xml 556 560 556 560 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">MEFV</italic>
###xml 800 804 800 804 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0008480-Zhang1">[18]</xref>
###xml 810 814 810 814 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">MEFV</italic>
###xml 977 984 977 984 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Table 1</bold>
###xml 977 984 977 984 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="table" rid="pone-0008480-t001"><bold>Table 1</bold></xref>
###xml 984 986 984 986 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">, </bold>
###xml 986 994 986 994 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Figure 1</bold>
###xml 986 994 986 994 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0008480-g001"><bold>Figure 1</bold></xref>
###xml 1361 1370 1361 1370 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="supplementary-material" rid="pone.0008480.s001">Figure S1</xref>
###xml 1361 1370 1361 1370 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML"><xref ref-type="supplementary-material" rid="pone.0008480.s001">Figure S1</xref></bold>
###xml 39 47 <span type="species:ncbi:9606">patients</span>
###xml 193 201 <span type="species:ncbi:9606">patients</span>
###xml 312 317 <span type="species:ncbi:9606">human</span>
###xml 755 762 <span type="species:ncbi:9606">patient</span>
Based on our previous finding that FMS patients and their family members had high plasma levels of several cytokines or chemokines compared to unrelated controls [18], we hypothesized that the patients had inherited an inflammatory gene. Although a large number of inflammatory genes have been identified in the human genome, the MEFV gene family stands out as one of the founding members of a subgroup containing the PYD domain that has been linked to the so called inflammasome. We therefore began our search for a candidate gene in FMS by analyzing the MEFV gene in one hundred probands with FMS and their parents, all meeting the ACR criteria for FMS, were recruited into the study, along with 2 affected siblings. The clinical characteristics of the patient population were previously published [18]. The MEFV gene was analyzed in the 100 trios by direct sequencing, a total of 2.63 megabases of genomic sequence. One common and 10 rare missense variants were identified (Table 1, Figure 1). Seven probands (FMS45, 127, 254, 316, 495, 501, 549) had one heterozygous rare mutation; five probands (FMS52, 248, 321, 411, 435) had two rare variants; and three probands and one affected sibling had three or more rare variants (FMS51, 53, 512, 540). The family pedigree for FMS53 revealed transmission of two different rare variant haplotypes for two siblings (Figure S1). In total, 15 out of 100 probands (and one affected sibling) carried one or more rare variants (15%) in 10 distinct rare haplotypes. In addition to these rare missense variants, the common missense polymorphism, R202Q, was identified in 40 probands (40/100 = 40%). The allele frequency of R202Q overall was 23% (46/200), compared with 29.6% reported in dbSNP controls.
###end p 21
###begin title 22
###xml 51 59 <span type="species:ncbi:9606">patients</span>
Missense mutation detected in the MEFV gene in FMS patients.
###end title 22
###begin p 23
###xml 40 44 40 44 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">MEFV</italic>
###xml 89 97 <span type="species:ncbi:9606">patients</span>
Part of the genomic organization of the MEFV gene and a map of the missense mutations in patients with Fibromyalgia Syndrome are illustrated.
###end p 23
###begin title 24
MEFV mutations identified in the trios.
###end title 24
###begin p 25
Infevers Database: ; a diagnosis of FMF requires compound heterozygotes.
###end p 25
###begin p 26
NCBI SNP database:
###end p 26
###begin p 27
###xml 62 69 62 69 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Table 1</bold>
###xml 62 69 62 69 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="table" rid="pone-0008480-t001"><bold>Table 1</bold></xref>
###xml 276 280 276 280 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">MEFV</italic>
###xml 429 441 429 441 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">collectively</bold>
###xml 567 579 567 579 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">collectively</bold>
###xml 694 701 694 701 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Table 2</bold>
###xml 694 701 694 701 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="table" rid="pone-0008480-t002"><bold>Table 2</bold></xref>
###xml 943 955 943 955 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">heterozygous</bold>
###xml 1030 1042 1030 1042 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">collectively</bold>
###xml 1173 1183 1173 1183 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="sec" rid="s3">Discussion</xref>
###xml 1443 1447 1443 1447 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0008480-Bernot1">[44]</xref>
###xml 1597 1605 1597 1605 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="supplementary-material" rid="pone.0008480.s004">Table S2</xref>
###xml 1597 1605 1597 1605 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML"><xref ref-type="supplementary-material" rid="pone.0008480.s004">Table S2</xref></bold>
###xml 1688 1692 1688 1692 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">MEFV</italic>
###xml 978 983 <span type="species:ncbi:9606">child</span>
Given that 15% of the probands had one or more rare variants (Table 1), and our intention was to determine if the rare variants were inherited in a biased manner, it was clear that the analysis of multiple subgroups would be underpowered. Based on the fact that multiple rare MEFV variants were capable of causing FMF if present on both chromosomes, we decided to test the transmission of rare variants from parents to offspring collectively. We hypothesized that FMS, unlike FMF, would require any of the rare variants on a single chromosome. Thus the rare variants collectively would create a risk for FMS but would require a further event such as an environmental factor to trigger disease. Table 2 lists the 22 independent events in which a rare allele was available for transmission from a parent to an affected proband or sibling. There are multiple lines for some families, with each line showing which haplotype was transmitted from a heterozygous parent to an affected child. As stated above, we tested the rare variants collectively for preferential transmission using the exact binomial version of the transmission disequilibrium test (TDT), as described in the Discussion section. In 17 of these 22 events (independent under the null hypothesis), the rare allele was transmitted to the affected offspring (p = 0.0085). The common allele R202Q was excluded from the analysis because it is frequently found in the general population [44] and does not qualify as rare. As expected, the same analysis for the common missense change, R202Q, showed no transmission bias to affected progeny (Table S2). Thus, we obtained evidence that rare alleles, encoding missense changes for the MEFV gene, were associated with FMS. The lack of biased transmission of the common allele from parents to probands suggested that R202Q does not correlate with risk of FMS and serves as an internal control for transmission of SNPs within this gene. It should be noted that in transmission analysis, the parents serve as the "controls" in that transmission of heterozygous rare alleles from parent to offspring should occur at a frequency of 0.5 by chance and >0.5 if associated with FMS.
###end p 27
###begin title 28
###xml 44 47 44 47 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="table-fn" rid="nt103">1,2</xref>
Transmission of rare variants for FMS trios.1,2
###end title 28
###begin p 29
Abbreviations are: wt-wildtype; het: heterozygote.
###end p 29
###begin p 30
###xml 182 188 182 188 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="supplementary-material" rid="pone.0008480.s001">Fig S1</xref>
Probands FMS52 and FMS53 are sisters that both inherited one set of rare alleles from the father, while one of the sisters inherited rare variants from her mother (see Supplementary Fig S1.)
###end p 30
###begin p 31
###xml 149 153 149 153 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0008480-Zhang1">[18]</xref>
###xml 272 276 272 276 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">MEFV</italic>
###xml 300 308 300 308 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Figure 2</bold>
###xml 300 308 300 308 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0008480-g002"><bold>Figure 2</bold></xref>
###xml 421 427 421 427 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">except</italic>
###xml 725 729 722 726 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">MEFV</italic>
###xml 777 781 774 778 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">MEFV</italic>
###xml 852 856 849 853 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">MEFV</italic>
###xml 945 949 938 942 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0008480-Locati1">[45]</xref>
###xml 991 995 984 988 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">MEFV</italic>
###xml 1057 1065 1050 1058 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Figure 2</bold>
###xml 1057 1065 1050 1058 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0008480-g002"><bold>Figure 2</bold></xref>
###xml 1342 1350 1335 1343 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Figure 2</bold>
###xml 1342 1350 1335 1343 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0008480-g002"><bold>Figure 2</bold></xref>
###xml 1578 1579 1571 1572 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">H</sub>
###xml 1597 1598 1586 1587 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">H</sub>
###xml 1634 1643 1623 1632 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="supplementary-material" rid="pone.0008480.s002">Figure S2</xref>
###xml 1634 1643 1623 1632 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML"><xref ref-type="supplementary-material" rid="pone.0008480.s002">Figure S2</xref></bold>
###xml 2052 2060 2037 2045 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Figure 2</bold>
###xml 2052 2060 2037 2045 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0008480-g002"><bold>Figure 2</bold></xref>
###xml 2128 2132 2109 2113 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0008480-Trinchieri1">[46]</xref>
###xml 2137 2138 2118 2119 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">H</sub>
###xml 2198 2207 2175 2184 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="supplementary-material" rid="pone.0008480.s002">Figure S2</xref>
###xml 2198 2207 2175 2184 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML"><xref ref-type="supplementary-material" rid="pone.0008480.s002">Figure S2</xref></bold>
###xml 2229 2230 2206 2207 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">H</sub>
###xml 40 48 <span type="species:ncbi:9606">patients</span>
###xml 388 396 <span type="species:ncbi:9606">patients</span>
###xml 586 594 <span type="species:ncbi:9606">patients</span>
###xml 754 762 <span type="species:ncbi:9606">patients</span>
###xml 828 836 <span type="species:ncbi:9606">patients</span>
###xml 1026 1034 <span type="species:ncbi:9606">patients</span>
###xml 1368 1376 <span type="species:ncbi:9606">patients</span>
###xml 1400 1407 <span type="species:ncbi:9606">patient</span>
###xml 1476 1484 <span type="species:ncbi:9606">patients</span>
###xml 1696 1704 <span type="species:ncbi:9606">patients</span>
###xml 1804 1812 <span type="species:ncbi:9606">patients</span>
Since we had previously shown that both patients and their parents had high plasma levels of MCP-1, IP-10 and eotaxin compared to unrelated controls [18], we decided to re-analyze these data to test if chemokine and/or cytokine plasma levels were correlated with the rare MEFV genotypes. As shown in Figure 2, MCP-1, IP-10 and eotaxin plasma levels were elevated, on average, for all FMS patients vs. unrelated controls, except those with the rare alleles for the MEFV gene, who were empirically intermediate, but cannot be statistically distinguished from either controls or other FMS patients. However, levels of IL-1beta, the chief cytokine associated with functional analysis of the pyrin protein (protein product of the MEFV gene), were high in FMS patients with the rare MEFV alleles, but not in unrelated controls or FMS patients with wild type MEFV. Plasma levels of MIP-1alpha, a chemokine involved in monocyte migration and activation [45], were elevated in subjects with the rare MEFV alleles compared to other FMS patients (p = 0.019, legend to Figure 2), who, along with their relatives, had elevated levels compared to unrelated controls. MCP-1, a chemokine with similar function, showed no such distinction of the individuals with rare alleles, but those with the R202Q polymorphism were strikingly elevated (p = 0.004, legend Figure 2) compared to FMS patients generally, and all FMS patient and family groups were elevated relative to unrelated controls. FMS patients and family members without rare variants differed from control subjects with regard to both TH1 (IFNgamma) and TH2 (IL-5 and IL-13) cytokine levels (Figure S2). Those with rare alleles were similar to other FMS patients and family with regard to IL-5 levels, but similar to control subjects and distinct from other FMS patients without rare variants (p = 0.003) with regard to IFNgamma, and indistinguishable from either group with regard to IL-13. However, we also noted a significant elevation for IL-12 plasma levels for all groups compared to unrelated controls (Figure 2). In spite of the expected relationship between IL-12 and IFNgamma [46] in TH1-like diseases, there was no elevation in IFNgamma levels (Figure S2), arguing against a TH1 involvement in FMS.
###end p 31
###begin title 32
###xml 36 40 36 40 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">MEFV</italic>
###xml 58 66 <span type="species:ncbi:9606">patients</span>
Plasma chemokine/cytokine levels by MEFV genotypes in FMS patients and family members, and in unrelated controls.
###end title 32
###begin p 33
###xml 204 208 204 208 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">MEFV</italic>
###xml 330 334 330 334 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">MEFV</italic>
###xml 709 713 709 713 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">MEFV</italic>
###xml 294 302 <span type="species:ncbi:9606">patients</span>
###xml 741 749 <span type="species:ncbi:9606">patients</span>
###xml 849 857 <span type="species:ncbi:9606">patients</span>
Ctrl: plasma levels (pg/mL) for unrelated controls (n = 77) of unknown genotype. Wt no FMS: unaffected parents without variant alleles (n = 35). Wt FMS: FMS probands (n = 37) with wild type (non-variant) MEFV gene. R202Q: FMS probands and family members with R202Q genotype (n = 49). Rare: FMS patients with a rare variant of the MEFV gene (n = 14). P values are shown below each group. Boxplots indicate the median (heavy bar), central 50% of data (box) and range of observations (whiskers). P-values are from two-sided t-tests contrasting each group with the control group, using pooled variance, a logarithmic scale, and without any adjustment for multiple comparisons. In addition, subjects with the rare MEFV alleles compared to wt FMS patients had elevated levels of MIP-1alpha (p = 0.019); subjects with R202Q polymorphism compared to wt FMS patients had elevated levels of MCP-1 (p = 0.004).
###end p 33
###begin title 34
Discussion
###end title 34
###begin title 35
###xml 12 16 12 16 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">MEFV</italic>
FMF-Related MEFV Variants
###end title 35
###begin p 36
###xml 72 76 72 76 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0008480-Zhang1">[18]</xref>
###xml 141 145 141 145 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">MEFV</italic>
###xml 197 202 197 202 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">NLRP3</italic>
###xml 727 731 727 731 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">MEFV</italic>
Since we have proposed that FMS has an underlying basis in inflammation [18], we began our search for a candidate gene with the well-studied MEFV gene associated with FMF. In addition, we examined NLRP3 (C1AS1 showed a single missense mutation in its exons) and 3 other genes associated with the inflammasome (ASC1, ASC2, and CD2BP1 exhibited no missense mutations in their exons). Since our cohort utilized trios, it was possible to measure transmission of haplotypes directly from parents to probands without the need for extensive matching of age, ethnicity, and other factors that might confound other designs. Thus, the parents serve as "controls" for the FMS affecteds. Among the genes analyzed (data not shown) only the MEFV gene displayed a significant result in terms of rare alleles that were transmitted from parents to probands. Of interest, these other genes collectively demonstrated only a few rare missense mutations.
###end p 36
###begin p 37
###xml 72 76 72 76 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">MEFV</italic>
###xml 609 616 609 616 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Table 1</bold>
###xml 609 616 609 616 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="table" rid="pone-0008480-t001"><bold>Table 1</bold></xref>
###xml 815 819 815 819 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0008480-Cazeneuve1">[47]</xref>
###xml 881 885 881 885 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">MEFV</italic>
###xml 1069 1073 1069 1073 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">MEFV</italic>
###xml 128 136 <span type="species:ncbi:9606">patients</span>
###xml 324 332 <span type="species:ncbi:9606">patients</span>
###xml 653 661 <span type="species:ncbi:9606">patients</span>
###xml 758 765 <span type="species:ncbi:9606">patient</span>
###xml 1039 1046 <span type="species:ncbi:9606">patient</span>
###xml 1178 1185 <span type="species:ncbi:9606">patient</span>
Our data herein provide strong evidence for the association between the MEFV structural gene variants and a subset (15%) of FMS patients. Of the 10 rare missense variants we identified, five are FMF-related mutations (E148Q, A289V, I591T, K695R, A744S; INFEVERS Database: .) E148Q is one of the most common mutations in FMF patients. It has been proposed that E148Q (together with another FMF allele) causes a milder disease, although some reports indicated E148Q should be classified as a polymorphism, rather than a disease-causing mutation, since it occurs at a higher frequency in the general population (Table 1). Interestingly, we found three FMS patients carrying three different mutations, E148Q/P369S/R408Q, which were reported previously in an FMF patient, all carried in cis on the same allele/haplotype [47]. No founder mutations (M680V, M694I, M694V and V726A) of the MEFV gene were identified in our study. These results support our diagnosis of FMS in this cohort, rather than variant FMF. Importantly, only a subset of the patient cohort carry the rare MEFV variants, leaving open the question of which genes are associated with risk in the remaining 85% of the patient cohort.
###end p 37
###begin title 38
Significance of the Common Mutation, R202Q
###end title 38
###begin p 39
###xml 60 64 60 64 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0008480-Bernot1">[44]</xref>
###xml 146 150 146 150 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0008480-Giaglis1">[48]</xref>
###xml 266 270 266 270 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0008480-Ritis1">[49]</xref>
###xml 532 536 532 536 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0008480-Ritis1">[49]</xref>
###xml 210 218 <span type="species:ncbi:9606">patients</span>
###xml 347 355 <span type="species:ncbi:9606">patients</span>
###xml 562 570 <span type="species:ncbi:9606">patients</span>
R202Q has previously been reported as a common polymorphism [44]. There is some evidence suggesting that R202Q homozygosity increases risk of FMF [48]. Homozygosity of R202Q has been detected in four of 26 FMF patients and none of 60 healthy individuals (p = 0.007, [49]). The lack of this homozygous alteration in 60 healthy individuals and nine patients suffering from other inflammatory diseases raises the possibility of a cooperative role for R202Q/R202Q in FMF. Although heterozygous R202Q is common among healthy individuals [49], its homozygosity in FMF patients may reflect a dosage-dependent deleterious effect that might require other genetic and environmental elements for expression. We identified six homozygous R202Q individuals in 100 FMS probands (6%). Analysis of a larger cohort and functional studies of the R2022Q variant pyrin protein may assist in understanding the role of this variant in both FMS and FMF.
###end p 39
###begin title 40
Statistical Methodology
###end title 40
###begin p 41
###xml 349 353 349 353 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0008480-McCarthy1">[50]</xref>
###xml 365 369 365 369 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0008480-Pritchard1">[51]</xref>
###xml 472 476 472 476 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0008480-Kryukov1">[43]</xref>
###xml 581 585 581 585 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0008480-Schork1">[52]</xref>
Collective testing of haplotypes carrying rare mutations is motivated by the variety of rare variants that contribute to FMF as compound heterozgotes and the variety of rare variants acting in a dominant mode at the cryopyrin gene. The collective testing of rare alleles at candidate genes is an increasingly common strategy in genetic epidemiology [50]. Pritchard [51] argues that rare alleles are, collectively, major contributors to common disorders; and Kryukov et al [43] assert that rarity of an allele is, by itself, an indicator of likely deleterious effect. Schork et al. [52] state that statistical testing of collections of rare variants, as a group, is a new but "crucial" development in genetic epidemiology.
###end p 41
###begin p 42
###xml 365 369 365 369 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">MEFV</italic>
###xml 1120 1121 1120 1121 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sup>
###xml 1300 1304 1300 1304 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0008480-Spielman1">[53]</xref>
###xml 86 91 <span type="species:ncbi:9606">child</span>
###xml 351 356 <span type="species:ncbi:9606">child</span>
Because we were interested in testing for dominant genetic effects (only one affected child was a compound heterozygote) and because no parents were compound heterozygotes, we were able to apply a particularly simple test. There were 22 transmission events in which a heterozygous parent could pass a chromosome with or without rare variants to their child. If the MEFV variants were neutral (the null hypothesis), either chromosome would be equally likely to be transmitted; furthermore, these events are stochastically independent. If rare variants increase the risk of FMS, then the fact that affected offspring are sampled will increase the probability of finding rare variants. We can simply count the number of transmissions and calculate the significance probability (p-value) from the binomial distribution, with event probability 0.5, and n = 22. This is a test of transmission, but it differs from the commonly used transmission/disequilibrium test (TDT) in that it tests rare variants collectively, is one-sided, and only involves only one mating type. The more commonly employed approximate test refers (b-c)2/(b+c) to a chi-square distribution, where b and c are the respective counts of transmitted and untransmitted candidate alleles from heterozygous parents; but, as Spielman et al. [53] noted when proposing this test, "An exact binomial test can be used, if desiredem leader" Spielman et al. go on to describe an application to multiple markers in the same manner that we use here; but, as they were concerned with markers, they imagined collecting alleles based on prior evidence of association rather than collecting uncommon missense variants. The major implications of using the TDT statistic to test a collection of uncommon missense sequences instead of markers are that (1) the test becomes one-sided (or there is no basis for collecting multiple variants); (2) the concern about segregation distortion is greatly reduced; and (3) the various marker-oriented characterizations of the TDT as a test of linkage in the presence of association become meaningless, as there is no marker.
###end p 42
###begin p 43
###xml 15 19 15 19 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0008480-Slager1">[54]</xref>
Slager, et al, [54] have shown that the TDT has a dramatic loss of power when there is allelic heterogeneity. Our one-sample binomial test handles allelic heterogeneity by simply counting all of the rare alleles, and maintains the advantages of a family-based test of linkage and association, essentially using untransmitted alleles as controls, which provides robustness against spurious conclusions induced by hidden genetic structure, such as stratification or admixture. Thus, there is no need to obtain and study age- and ethnicity-matched controls.
###end p 43
###begin p 44
###xml 187 191 187 191 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0008480-Schork1">[52]</xref>
###xml 333 337 333 337 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">MEFV</italic>
###xml 419 423 419 423 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">MEFV</italic>
###xml 36 41 <span type="species:ncbi:9606">human</span>
###xml 171 176 <span type="species:ncbi:9606">human</span>
###xml 495 503 <span type="species:ncbi:9606">patients</span>
There is a growing discussion among human geneticists that collections of rare alleles at pathogenetic loci will account for a significant proportion of genetically-based human disorders [52]. Thus, we feel confident that the analysis presented here is the most appropriate test for studying the possible association of FMS with the MEFV gene at this early stage of analysis. Our data suggest that transmission of rare MEFV alleles constitutes a strong risk factor, but only for a subset of FMS patients.
###end p 44
###begin title 45
Correlative Studies
###end title 45
###begin p 46
###xml 24 28 24 28 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">MEFV</italic>
###xml 371 375 368 372 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0008480-Zhang1">[18]</xref>
###xml 599 603 593 597 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">MEFV</italic>
###xml 1270 1274 1261 1265 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0008480-Sprott1">[22]</xref>
###xml 1397 1401 1385 1389 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0008480-Gavrilin1">[55]</xref>
###xml 1588 1592 1573 1577 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0008480-Zhang1">[18]</xref>
###xml 1692 1696 1677 1681 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0008480-Ogilvie1">[56]</xref>
###xml 1890 1894 1875 1879 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0008480-Sun1">[57]</xref>
###xml 1943 1947 1928 1932 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0008480-Sell1">[58]</xref>
###xml 2126 2130 2111 2115 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">MEFV</italic>
###xml 210 218 <span type="species:ncbi:9606">patients</span>
###xml 286 294 <span type="species:ncbi:9606">patients</span>
###xml 458 466 <span type="species:ncbi:9606">patients</span>
###xml 580 588 <span type="species:ncbi:9606">patients</span>
###xml 773 781 <span type="species:ncbi:9606">patients</span>
###xml 865 873 <span type="species:ncbi:9606">patients</span>
###xml 1216 1224 <span type="species:ncbi:9606">patients</span>
The correlation of rare MEFV alleles with elevated chemokine/cytokine plasma levels is especially intriguing because functional studies on the pyrin protein would predict disregulation of IL-1beta secretion in patients with chronic inflammation. In our previous analysis on a subset of patients and parents with FMS, we found elevation of MCP-1 and eotaxin plasma levels [18], but the standard deviation on IL-1beta levels was large in both controls and FMS patients, providing no significant difference between the two groups. However, upon re-analysis of the data comparing FMS patients with rare MEFV alleles to controls, IL-1beta was significantly elevated (p = 0.019). This is the first demonstration of such a correlation and merits further study in both FMS and FMF patients. What remains unexplained is the cause of the high MCP-1 and eotaxin levels in FMS patients, regardless of their genotype. This suggests that there is an environmental component to the disease, most likely underlying chronic inflammation, since many inflammatory stimuli will cause the production of MCP-1, which, in turn, will activate monocytes. While no evidence of monocytic infiltrates into skeletal muscle has been found in FMS patients, there is evidence of skeletal muscle damage [22] that may be caused by high systemic levels of MCP-1. MCP-1 has been shown to up-regulate IL-1beta expression in monocytes [55]. The specific interaction of MCP-1 with skeletal muscle has not been studied in detail, but we have shown that MCP-1 stimulates the release of IL-1beta, IP-10 and eotaxin from myoblasts [18]. In addition, eotaxin is the natural antagonist for the CCR2 receptor, the main receptor for MCP-1 [56]. Thus, high levels of eotaxin may reflect an attempt by skeletal muscle (or other cells) to counteract the effects of MCP-1. Finally, MCP-1 has a direct effect on sensory neurons, causing pain [57], and reduces glucose uptake in skeletal muscles [58], possibly subjecting skeletal muscles to fatigue. What remains to be explored is the complex connection between the effect of mutations in inflammation-regulating genes, such as MEFV, and environmental effects that sustain the production of harmful chemokines and cytokines, such as MCP-1, eotaxin, and IL-1beta.
###end p 46
###begin p 47
###xml 272 276 269 273 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">MEFV</italic>
###xml 432 433 425 426 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">H</sub>
###xml 530 531 519 520 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">H</sub>
###xml 648 649 637 638 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">H</sub>
###xml 655 656 644 645 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">H</sub>
###xml 714 718 703 707 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">MEFV</italic>
###xml 889 893 875 879 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">MEFV</italic>
###xml 77 85 <span type="species:ncbi:9606">patients</span>
###xml 253 261 <span type="species:ncbi:9606">patients</span>
###xml 313 321 <span type="species:ncbi:9606">patients</span>
###xml 695 703 <span type="species:ncbi:9606">patients</span>
The lack of the usual wide variation in plasma MCP-1 and IP-10 levels in FMS patients with the common R202Q allele may indicate that this variant has a functional connection to the production of these two cytokines, rather than IL-1beta, as seen in the patients with rare MEFV alleles. It is also noteworthy that patients with the common polymorphism have depressed levels of IFNgamma and IL-13, the former demonstrating a lack of TH1-like disease (where high IFNgamma and low IL-13 are expected), and the latter arguing against TH2-like disease, such as asthma (where high IL-4 and IL-13 are expected). Taken together, these data argue against a TH1 or TH2 origin for the disease in the 15% of patients with rare MEFV alleles and the 40% of probands with the common variant. (In this regard, it is interesting that IL-1beta is associated with innate immunity.) Thus, polymorphisms in the MEFV gene may predispose up to 55% of probands to an immunological imbalance in cytokine/chemokine levels.
###end p 47
###begin p 48
Finally, we have accounted for a possible disease susceptibility gene in only a subset of FMS. Given the large number of NLR genes and their growing number of disease associations, it is likely that more NLR gene variants will be found as risk factors for FMS, and that specific chronic infections will be identified that trigger FMS via their interactions with these genes. Therefore, we are hopeful that the etiology of FMS will emerge along with its correlation to genetic risk factors. Importantly, the studies presented here are correlative and do not provide a mechanistic explanation for FMS. Studies are now underway to determine if the rare variants identified confer a phenotype to transfected cell lines.
###end p 48
###begin title 49
Methods
###end title 49
###begin title 50
Subjects
###end title 50
###begin p 51
###xml 408 411 408 411 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0008480-Wolfe3">[3]</xref>
###xml 634 638 634 638 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0008480-Zhang1">[18]</xref>
###xml 692 696 692 696 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0008480-Zhang1">[18]</xref>
###xml 110 118 <span type="species:ncbi:9606">Patients</span>
###xml 302 314 <span type="species:ncbi:9606">participants</span>
###xml 413 421 <span type="species:ncbi:9606">Patients</span>
###xml 584 591 <span type="species:ncbi:9606">patient</span>
The study was approved by the Institutional Review Board of City of Hope National Medical Center (IRB 04186). Patients with fibromyalgia recruited into the study contacted their first-degree relatives, who were subsequently also recruited into the study. Written informed consent was obtained from all participants in this study. Probands and affected parents were diagnosed with FMS fulfilling ACR criteria [3]. Patients with the autoimmune diseases rheumatoid arthritis (RA) and systemic lupus erythematosus (SLE) were excluded from the study; other clinical characteristics of the patient population have been previously described [18]. Unrelated control subjects, as previously described [18] were used for comparison of cytokine/chemokine levels, but the genetic analysis used the transmission disequilibrium test, which avoids the need for unaffected control subjects.
###end p 51
###begin title 52
PCR and Sequencing
###end title 52
###begin p 53
###xml 258 262 258 262 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">MEFV</italic>
###xml 372 373 368 369 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sub>
###xml 1046 1054 1004 1012 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="supplementary-material" rid="pone.0008480.s003">Table S1</xref>
###xml 1046 1054 1004 1012 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML"><xref ref-type="supplementary-material" rid="pone.0008480.s003">Table S1</xref></bold>
###xml 1093 1097 1051 1055 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">MEFV</italic>
DNA was isolated from peripheral leukocytes or saliva, using the QIAamp DNA Blood Mini Kit (Qiagen) and Oragene DNA Self Collection Kits (DNA Genotek) according to the manufacturers' instructions. All coding exons and splice junctions (except exon 2) of the MEFV gene were amplified by PCR in a total volume of 20 microl with 10 mM Tris-HCl, pH 8.3, 50 mM KCl, 1.5 mM MgCl2, 200 microM of each deoxyribonucleoside triphosphate, and 0.2 microM of primers. 1 U of Ampli-Taq Gold (Roche) and 20 ng of genomic DNA were added. Exon 2 was amplified with the GC-RICH PCR System (Roche). PCR reactions were performed on the GeneAmp PCR System 9700 (Applied Biosystems) with denaturation at 94degreesC for 10 min, and then denaturation at 94degreesC for 15 sec, annealing at 60degreesC for 30 sec, and elongation at 72degreesC for 1 min for a total of 35 cycles and a final elongation for 10 min at 72degreesC. The amplicons were purified by ExoSAP-IT and sequenced with the ABI PRISM 3730 (Applied Biosystems). The sequences of PCR primers are listed in Table S1. Genomic and amino acid sequences for MEFV were collected from Ensemble: ENST00000219596, ENSG00000103313.
###end p 53
###begin title 54
Statistical Analysis
###end title 54
###begin p 55
###xml 62 72 62 72 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="sec" rid="s3">Discussion</xref>
The statistical considerations are described in detail in the Discussion section.
###end p 55
###begin title 56
Measurement of Cytokines and Chemokines
###end title 56
###begin p 57
###xml 112 116 112 116 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0008480-Zhang1">[18]</xref>
###xml 212 216 212 216 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">MEFV</italic>
###xml 228 232 228 232 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">MEFV</italic>
The plasma level of cytokines and chemokines of a portion of the cohort described here were previously reported [18]. The levels were compared in unrelated controls and probands and family members with wild type MEFV or variant MEFV alleles. Statistical analysis was performed by a two sided, unpaired student's t test.
###end p 57
###begin title 58
Supporting Information
###end title 58
###begin p 59
Pedigree for family 13 that transmitted multiple rare alleles to two different offspring. Filled circles are females with FMS, open square, unaffected father.
###end p 59
###begin p 60
(0.54 MB TIF)
###end p 60
###begin p 61
Click here for additional data file.
###end p 61
###begin p 62
###xml 276 280 276 280 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">MEFV</italic>
###xml 402 406 402 406 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">MEFV</italic>
###xml 60 68 <span type="species:ncbi:9606">patients</span>
###xml 366 374 <span type="species:ncbi:9606">patients</span>
Cytokines that inversely correlate with rare alleles in FMS patients and their families. Ctrl: plasma levels (pg/mL) for unrelated controls (n = 77), unknown genotype. Wt no FMS: parents with wild type alleles and no FMS (n = 35). Wt FMS: FMS probands (n = 37) with wild type MEFV gene. R202Q: FMS probands and family members with R202Q genotype (n = 49). Rare: FMS patients with a rare variant of the MEFV gene (n = 14). P values are shown below each group. Boxplots indicate the median (heavy bar), central 50% of data (box) and range of observations (wiskers). P-values are from two-sided t-tests contrasting each group with the control group, using pooled variance, a logarithmic scale, and without any adjustment for multiple comparisons.
###end p 62
###begin p 63
(1.00 MB TIF)
###end p 63
###begin p 64
Click here for additional data file.
###end p 64
###begin p 65
###xml 16 20 16 20 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">MEFV</italic>
Primers for the MEFV gene.
###end p 65
###begin p 66
(0.04 MB DOC)
###end p 66
###begin p 67
Click here for additional data file.
###end p 67
###begin p 68
Genotype of R202Q in trios.
###end p 68
###begin p 69
(0.07 MB DOC)
###end p 69
###begin p 70
Click here for additional data file.
###end p 70
###begin title 71
References
###end title 71
###begin article-title 72
###xml 36 44 <span type="species:ncbi:9606">patients</span>
Assessment of functional ability in patients with fibromyalgia.
###end article-title 72
###begin article-title 73
The prevalence and characteristics of fibromyalgia in the general population.
###end article-title 73
###begin article-title 74
The American College of Rheumatology 1990 Criteria for the Classification of Fibromyalgia. Report of the Multicenter Criteria Committee.
###end article-title 74
###begin article-title 75
###xml 71 79 <span type="species:ncbi:9606">patients</span>
Fibromyalgia syndrome (FM) and nonarticular tenderness in relatives of patients with FM.
###end article-title 75
###begin article-title 76
Family study of fibromyalgia.
###end article-title 76
###begin article-title 77
Importance of genetic influences on chronic widespread pain.
###end article-title 77
###begin article-title 78
Familial aggregation in the fibromyalgia syndrome.
###end article-title 78
###begin article-title 79
Pain management in fibromyalgia.
###end article-title 79
###begin article-title 80
###xml 57 65 <span type="species:ncbi:9606">patients</span>
Duloxetine and other antidepressants in the treatment of patients with fibromyalgia.
###end article-title 80
###begin article-title 81
Experimental evaluation of an altered tryptophan metabolism in fibromyalgia.
###end article-title 81
###begin article-title 82
Confirmation of an association between fibromyalgia and serotonin transporter promoter region (5- HTTLPR) polymorphism, and relationship to anxiety-related personality traits.
###end article-title 82
###begin article-title 83
Possible association of fibromyalgia with a polymorphism in the serotonin transporter gene regulatory region.
###end article-title 83
###begin article-title 84
The T102C polymorphism of the 5-HT2A-receptor gene in fibromyalgia.
###end article-title 84
###begin article-title 85
Association of T102C polymorphism of the 5-HT2A receptor gene with psychiatric status in fibromyalgia syndrome.
###end article-title 85
###begin article-title 86
Significance of catechol-O-methyltransferase gene polymorphism in fibromyalgia syndrome.
###end article-title 86
###begin article-title 87
An association between fibromyalgia and the dopamine D4 receptor exon III repeat polymorphism and relationship to novelty seeking personality traits.
###end article-title 87
###begin article-title 88
The genetics of fibromyalgia syndrome.
###end article-title 88
###begin article-title 89
High plasma levels of MCP-1 and eotaxin provide evidence for an immunological basis of fibromyalgia.
###end article-title 89
###begin article-title 90
Etiology of fibromyalgia: the possible role of infection and vaccination.
###end article-title 90
###begin article-title 91
Autoimmune diseases and infections: controversial issues.
###end article-title 91
###begin article-title 92
Pathogenesis of fibromyalgia - a review.
###end article-title 92
###begin article-title 93
Increased DNA fragmentation and ultrastructural changes in fibromyalgic muscle fibres.
###end article-title 93
###begin article-title 94
Family history of irritable bowel syndrome is the major determinant of persistent abdominal complaints in young adults with a history of pediatric recurrent abdominal pain.
###end article-title 94
###begin article-title 95
Fibromyalgia in the irritable bowel syndrome: studies of prevalence and clinical implications.
###end article-title 95
###begin article-title 96
###xml 89 96 <span type="species:ncbi:9606">patient</span>
Familial Mediterranean fever and the other autoinflammatory syndromes: evaluation of the patient with recurrent fever.
###end article-title 96
###begin article-title 97
Familial Mediterranean fever.
###end article-title 97
###begin article-title 98
Function of Nod-like receptors in microbial recognition and host defense.
###end article-title 98
###begin article-title 99
NOD-like receptors and inflammation.
###end article-title 99
###begin article-title 100
Nod-like Receptors: Role in Innate Immunity and Inflammatory Disease.
###end article-title 100
###begin article-title 101
NLR, the nucleotide-binding domain leucine-rich repeat containing gene family.
###end article-title 101
###begin article-title 102
The PYRIN domain in signal transduction.
###end article-title 102
###begin article-title 103
The pyrin family of fever genes: unmasking genetic determinants of autoinflammatory disease.
###end article-title 103
###begin article-title 104
The inflammasome: a caspase-1-activation platform that regulates immune responses and disease pathogenesis.
###end article-title 104
###begin article-title 105
###xml 148 156 <span type="species:ncbi:9606">patients</span>
Disease-associated CIAS1 mutations induce monocyte death, revealing low-level mosaicism in mutation-negative cryopyrin-associated periodic syndrome patients.
###end article-title 105
###begin article-title 106
Mutations in cryopyrin: bypassing roadblocks in the caspase 1 inflammasome for interleukin-1beta secretion and disease activity.
###end article-title 106
###begin article-title 107
###xml 85 93 <span type="species:ncbi:9606">patients</span>
The clinical continuum of cryopyrinopathies: novel CIAS1 mutations in North American patients and a new cryopyrin model.
###end article-title 107
###begin article-title 108
Critical role for NALP3/CIAS1/Cryopyrin in innate and adaptive immunity through its regulation of caspase-1.
###end article-title 108
###begin article-title 109
Molecular basis of the spectral expression of CIAS1 mutations associated with phagocytic cell-mediated autoinflammatory disorders CINCA/NOMID, MWS, and FCU.
###end article-title 109
###begin article-title 110
Pyrin and cryopyrin-similar domain sequence but opposite inflammatory consequence.
###end article-title 110
###begin article-title 111
The molecular basis of NOD2 susceptibility mutations in Crohn's disease.
###end article-title 111
###begin article-title 112
NOD2 regulation of Toll-like receptor responses and the pathogenesis of Crohn's disease.
###end article-title 112
###begin article-title 113
HIN-200 proteins regulate caspase activation in response to foreign cytoplasmic DNA.
###end article-title 113
###begin article-title 114
###xml 46 52 <span type="species:ncbi:9606">humans</span>
Most rare missense alleles are deleterious in humans: implications for complex disease and association studies.
###end article-title 114
###begin article-title 115
Non-founder mutations in the MEFV gene establish this gene as the cause of familial Mediterranean fever (FMF).
###end article-title 115
###begin article-title 116
Chemokines and chemokine receptors: biology and clinical relevance in inflammation and AIDS.
###end article-title 116
###begin article-title 117
Interleukin-12 and the regulation of innate resistance and adaptive immunity.
###end article-title 117
###begin article-title 118
###xml 31 39 <span type="species:ncbi:9606">patients</span>
MEFV-Gene analysis in armenian patients with Familial Mediterranean fever: diagnostic value and unfavorable renal prognosis of the M694V homozygous genotype-genetic and therapeutic implications.
###end article-title 118
###begin article-title 119
###xml 77 85 <span type="species:ncbi:9606">patients</span>
MEFV alterations and population genetics analysis in a large cohort of Greek patients with familial Mediterranean fever.
###end article-title 119
###begin article-title 120
###xml 142 150 <span type="species:ncbi:9606">patients</span>
Non-isotopic RNase cleavage assay for mutation detection in MEFV, the gene responsible for familial Mediterranean fever, in a cohort of Greek patients.
###end article-title 120
###begin article-title 121
Exploring the unknown: assumptions about allelic architecture and strategies for susceptibility variant discovery. Oxford: University of Oxford.
###end article-title 121
###begin article-title 122
Are rare variants responsible for susceptibility to complex diseases?
###end article-title 122
###begin article-title 123
Common vs. rare allele hypotheses for complex diseases.
###end article-title 123
###begin article-title 124
Transmission test for linkage disequilibrium: the insulin gene region and insulin-dependent diabetes mellitus (IDDM).
###end article-title 124
###begin article-title 125
Effect of allelic heterogeneity on the power of the transmission disequilibrium test.
###end article-title 125
###begin article-title 126
###xml 66 71 <span type="species:ncbi:9606">human</span>
Monocyte chemotactic protein 1 upregulates IL-1beta expression in human monocytes.
###end article-title 126
###begin article-title 127
Eotaxin is a natural antagonist for CCR2 and an agonist for CCR5.
###end article-title 127
###begin article-title 128
MCP-1 enhances excitability of nociceptive neurons in chronically compressed dorsal root ganglia.
###end article-title 128
###begin article-title 129
Monocyte chemotactic protein-1 is a potential player in the negative cross-talk between adipose tissue and skeletal muscle.
###end article-title 129
###begin p 130
###xml 0 21 0 21 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Competing Interests: </bold>
Competing Interests: The authors have declared that no competing interests exist.
###end p 130
###begin p 131
###xml 0 9 0 9 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Funding: </bold>
Funding: This research was supported by a grant from the Los Angeles Fibromyalgia Foundation and in part by an National Institutes of Health General Clinical Research Center Grant, M01 RR00043. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.
###end p 131

